PHL Treatment for Pancreatic Cancer
EARLY_PHASE1
20
about 5.2 years
18+
1 site in PA
What this study is about
This trial is testing a new treatment called PHL (paricalcitol, hydroxychloroquine, and losartan) in people with pancreatic cancer. The goal of this early-phase trial is to see if PHL can be safely used before surgery. This will help determine if PHL has any effect on the tumor and its surrounding tissue.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Paricalcitol, Hydroxychloroquine, Losartan
- 2.Undergo Neoadjuvant therapy and surgery only (Control)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
hydroxychloroquine (Antimalarial; increases pH in parasite), losartan (ARB; blocks angiotensin II receptor to lower blood pressure), paricalcitol, antimalarial (Antimalarial; increases pH in parasite)
oral (Oral Capsule), oral
Primary: Number of participants who experience grade 3 or greater treatment-related adverse events assessed by CTCAE v5.0